The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

(2021) José María Piulats et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development

(2020) Carlos R. Figueiredo et al.   JOURNAL OF PATHOLOGY

The mutational constraint spectrum quantified from variation in 141,456 humans

(2020) Konrad J. Karczewski et al.   NATURE

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

(2020) Peter A. Johansson et al.   Nature Communications

Molecular profiling of driver events in metastatic uveal melanoma

(2020) Joakim Karlsson et al.   Nature Communications

Uveal melanoma

(2020) Martine J. Jager et al.   Nature Reviews Disease Primers

Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer

(2020) Michele Carbone et al.   Cancer Discovery

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

(2020) Yana G Najjar et al.   Journal for ImmunoTherapy of Cancer

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

(2020) Gabriela Marsavela et al.   CLINICAL CANCER RESEARCH

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

(2020) Mark R. Middleton et al.   CLINICAL CANCER RESEARCH

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

(2020) Yang Gao et al.   NATURE CELL BIOLOGY

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

(2020) Meredith S. Pelster et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis

(2019) Douglas B. Johnson et al.   Journal of the National Comprehensive Cancer Network

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

(2019) Peter A. Johansson et al.   IMMUNOGENETICS

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

(2019) Henrik Jespersen et al.   BMC CANCER

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

(2019) L Khoja et al.   ANNALS OF ONCOLOGY

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

(2019) Jhanelle E. Gray et al.   CLINICAL CANCER RESEARCH

The emerging role of epigenetic therapeutics in immuno-oncology

(2019) Michael J. Topper et al.   Nature Reviews Clinical Oncology

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers

(2019) Jeffim N. Kuznetsov et al.   Science Advances

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

(2019) Cristina P. Rodriguez et al.   CLINICAL CANCER RESEARCH

Integrating single-cell transcriptomic data across different conditions, technologies, and species

(2018) Andrew Butler et al.   NATURE BIOTECHNOLOGY

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

(2018) Manuel Rodrigues et al.   Nature Communications

MutationalPatterns: comprehensive genome-wide analysis of mutational processes

(2018) Francis Blokzijl et al.   Genome Medicine

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

(2018) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

1247PDPhase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

(2018) J M Piulats Rodriguez et al.   ANNALS OF ONCOLOGY

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs

(2018) Brian J. Christmas et al.   Cancer Immunology Research

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

(2018) Claire Mignard et al.   Journal of Oncology

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

(2017) Mario Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

(2017) Smita S Chandran et al.   LANCET ONCOLOGY

Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing

(2017) Anders Ståhlberg et al.   Nature Protocols

Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing

(2016) Beryl Royer-Bertrand et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

(2016) Alain P. Algazi et al.   CANCER

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing

(2016) Eric Talevich et al.   PLoS Computational Biology

Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets

(2016) Laurent Muller et al.   Scientific Reports

A global reference for human genetic variation

(2015) Richard A. Gibbs et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors

(2015) Joseph J. Sacco et al.   Oncotarget

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Phase II trial of vorinostat in advanced melanoma

(2014) N. B. Haas et al.   INVESTIGATIONAL NEW DRUGS

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

(2014) Joydeep Bhadury et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma

(2013) Katie A Matatall et al.   BMC CANCER

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma

(2011) S. Landreville et al.   CLINICAL CANCER RESEARCH

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

(2008) M Campoli et al.   ONCOGENE